Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)

Core Insights - Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on developing oral covalent small molecules for treating diabetes, obesity, and genetically defined cancers [2][3] - The company will present topline results from its Phase II trial, COVALENT-111, for icovamenib in patients with type 2 diabetes on December 17, 2024 [1] Company Overview - Biomea Fusion specializes in the discovery and development of covalent small molecules, which form permanent bonds to target proteins, offering advantages such as greater target selectivity and lower drug exposure [2] - The company utilizes its proprietary FUSION™ System to design and develop next-generation covalent-binding small-molecule medicines aimed at maximizing clinical benefits for patients [3] Event Details - A conference call and webcast will be held on December 17, 2024, at 8:00 am EST to discuss the trial results, with a replay available on the company's website [1][2]